Inogen
Portable oxygen concentrators for home care
R&D Engineering Intern - Remote Therapeutic Monitoring
About the job
- Pursuing a Bachelor’s or Master’s degree in Data Science.
- Pursuing a Bachelor’s or Master’s degree in Computer Science.
- Pursuing a Bachelor’s or Master’s degree in Biomedical Engineering.
- Pursuing a Bachelor’s or Master’s degree in Health Informatics.
- Pursuing a Bachelor’s or Master’s degree in Public Health.
- Pursuing a Bachelor’s or Master’s degree in related fields.
- Proficiency in Python with experience using pandas, NumPy, matplotlib, and seaborn.
- Assist in creating low-fidelity wireframes for an RTM mobile app focusing on usage tracking, symptom entry, reminders, and progress screens, with a deliverable of a clickable prototype (Figma or similar) showing at least three user flows.
- Prototype simple rule-based digital nudges, such as reminders triggered when usage is low or symptoms worsen, with a deliverable of a logic map and sample message library for patient engagement.
- Map the end-to-end digital patient journey for RTM, including device activation, data, patient-reported outcomes, and provider dashboards, with a deliverable of a visual single-slide workflow showing data touchpoints and RTM billing considerations.
- Define the minimum set of patient-reported outcomes for Chronic Obstructive Pulmonary Disease and bronchiectasis RTM, with a deliverable of a PRO list and a proposed scoring rubric for Inogen’s digital health platform.
- Propose adherence and response key performance indicators for internal dashboards (e.g., adherence percentage, symptom stability, session variability), with a deliverable of a dashboard mockup in Power BI, Tableau, or Figma.
- Experience with Power BI or Tableau for dashboards.
- Experience in digital health, respiratory care, medical devices, or patient-centered design is preferred.
- Experience creating prototype digital health application flows is preferred.
- Strong writing and communication skills are desirable.
About the company
Inogen makes and sells portable oxygen concentrators for people with chronic breathing problems like COPD. These devices pull in air from the surroundings, remove nitrogen, and deliver concentrated oxygen to the user, allowing them to move around and stay independent while receiving oxygen therapy. The product is designed to be light and easy to carry, with models available to buy or rent directly from Inogen, and through a network of distributors and home medical equipment providers. What sets Inogen apart is its direct-to-consumer approach (and rental option) that bypasses traditional durable medical equipment sellers, aiming to build direct relationships with patients. The company operates in the home medical equipment market, targeting those who need long-term oxygen therapy. Its goal is to improve patients’ quality of life by providing portable, user-friendly oxygen solutions and expanding access to oxygen therapy.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Goleta, California
Founded
2001
Get referred to Inogen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Aurora CPAP masks launched January 2026; customer accounts more than doubled by Q2 2026.
- Inogen raised 2026 adjusted EBITDA guidance to about $4 million after Q2 margin gains.
- Cash of $106.8 million and no debt fund R&D and buybacks through 2026.
What critics are saying
- Inogen cut 2026 revenue guidance to $355-$361 million after Q2 U.S. sales fell 2.3%.
- U.S. rental revenue dropped 11.8% in Q2 2026, exposing direct-channel weakness and customer churn.
- FDA MAUDE reports in March and June 2026 show overheating, fire, and low-oxygen injuries.
What makes Inogen unique
- Inogen's 2026 platform spans oxygen, sleep apnea, and airway clearance, not single-product dependence.
- Yuwell's January 2025 $27.2 million stake gives Inogen Chinese manufacturing and distribution leverage.
- International revenue grew 14.8% in Q2 2026, sustaining ten consecutive double-digit quarters.
Help us improve and share your feedback! Did you find this helpful?
Benefits
401(k) Retirement Plan
401(k) Company Match
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Inogen reported breakeven earnings for Q2 2026, beating the Zacks Consensus Estimate by 17.7%. This compares to an adjusted loss of 2 cents per share in the prior-year quarter. Revenues reached $95.1 million, up 3% year over year and slightly ahead of estimates. The growth was driven by strong international demand for portable oxygen concentrators, favourable exchange rates and new product contributions. International sales climbed 14.8% to $41.3 million, marking the 10th consecutive quarter of double-digit growth. However, US sales declined 2.3% to $42.3 million, whilst US rental revenues fell 11.8% to $11.6 million. Adjusted gross margin improved 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Year to date, Inogen's shares have fallen 10%.
Inogen reported strong international revenue growth of 15% year-over-year in Q2 2026, marking its 10th consecutive quarter of double-digit international growth. The company's core portable oxygen concentrator unit volume grew over 12%, outpacing overall market growth. Gross margin expanded by 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Inogen raised its full-year adjusted EBITDA guidance to approximately $4 million, representing 48% growth over 2025. However, the company lowered its full-year revenue guidance to $355–361 million from $366–373 million. US sales declined 2% year-over-year due to channel mix challenges, whilst US rental revenue decreased 12%. New products Voxy and Aurora are gaining traction, with Voxy shipping over 5,000 units. Inogen maintains a strong balance sheet with $106.8 million in cash and no debt.
Yuwell Medical has announced a strategic investment in Inogen, a US-based respiratory health company. Through its Hong Kong subsidiary, Yuwell will invest approximately $27.2 million for a 9.9% stake in Inogen's common stock. The partnership will focus on four key areas: international distribution, trademark licensing, joint research and development, and supply chain optimisation. Both companies specialise in oxygen concentrators and aim to combine their expertise across different markets. At Yuwell's 2025 Global Core Partner Conference, Chairman Alex Wu outlined the company's five-year vision to become one of the top three global players in home medical health. Yuwell identified respiratory treatment solutions, diabetes care, and emergency services as its three strategic priorities for international expansion.
Inogen, a medical technology company specialising in respiratory products, has appointed Andy Reding as Chief Operating Officer, effective 6 July 2026. Reding will oversee revenue and operational performance whilst aligning cross-functional priorities as the company pursues new product launches and geographic expansion. Reding brings over 30 years of experience in medical technology. Most recently, he served as Chief Commercial Officer at Viant Medical for six years, where he led teams across 25 facilities. He previously held leadership roles at Hillrom Respiratory Health, managing sales, marketing and product development. As part of his employment, Reding will receive 130,000 restricted stock units vesting over three years. He holds an MBA from the University of South Carolina and a bachelor's degree from Marquette University.
Inogen, a medical technology company offering respiratory products, reported first-quarter 2026 revenue of $85.1 million, up 3.4% year-over-year, exceeding guidance. The company reiterated its full-year 2026 revenue outlook of $366 million to $373 million. The Beverly, Massachusetts-based firm posted a GAAP net loss of $8.3 million, compared to a $6.2 million loss in the prior-year period. Adjusted EBITDA was negative $1.4 million, down from positive $0.04 million a year earlier, due to increased research and development investments. Inogen authorised a $30 million share repurchase programme and appointed Jason Richardson as chief financial officer. The company also launched Aurora CPAP masks in the US, entering the obstructive sleep apnea market, and introduced its Rove 6 portable oxygen concentrator in Brazil.